Clevidipine

Results: 65



#Item
11

PDF Document

Add to Reading List

Source URL: www.phassociation.org

Language: English - Date: 2013-12-03 14:16:12
12HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use MYRBETRIQTM safely and effectively. See full prescribing information for MYRBETRIQ.  	 Patients Taking Drugs Meta

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use MYRBETRIQTM safely and effectively. See full prescribing information for MYRBETRIQ.  Patients Taking Drugs Meta

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2012-06-28 14:48:40
13•	 Reversible Posterior Leukoencephalopathy Syndrome (RPLS) has been observed and can be fatal. Permanently discontinue VOTRIENT in patients developing RPLS. (5.9) •	 Hypertension including hypertensive crisis has be

• Reversible Posterior Leukoencephalopathy Syndrome (RPLS) has been observed and can be fatal. Permanently discontinue VOTRIENT in patients developing RPLS. (5.9) • Hypertension including hypertensive crisis has be

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2014-11-19 13:09:31
14HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ICLUSIG safely and effectively. See full prescribing information for ICLUSIG. ICLUSIG® (ponatinib) tablets for oral

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ICLUSIG safely and effectively. See full prescribing information for ICLUSIG. ICLUSIG® (ponatinib) tablets for oral

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2014-07-25 12:30:45
15CYRAMZA (ramucirumab) injection Label

CYRAMZA (ramucirumab) injection Label

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2014-11-05 13:17:59
16Microsoft Word - Nicardipine DHPC letter_FINAL

Microsoft Word - Nicardipine DHPC letter_FINAL

Add to Reading List

Source URL: www.mhra.gov.uk

Language: English - Date: 2014-10-14 07:40:20
17Learning from recent trials and shaping the future of acute heart failure trials

Learning from recent trials and shaping the future of acute heart failure trials

Add to Reading List

Source URL: www.globalcvctforum.com

Language: English - Date: 2014-06-11 09:59:56
18•	 Venou s thromboembolic events (VTE) have been observed, including fatal pulmonary emboli (PE). Monitor for signs and symptoms of VTE and PE. (5.6) •	 Thrombotic microa ngiopathy (TMA), including thrombotic thrombo

• Venou s thromboembolic events (VTE) have been observed, including fatal pulmonary emboli (PE). Monitor for signs and symptoms of VTE and PE. (5.6) • Thrombotic microa ngiopathy (TMA), including thrombotic thrombo

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2014-06-04 14:49:21
19Agalsidase beta, Fabrazyme,  Genzyme Corp

Agalsidase beta, Fabrazyme, Genzyme Corp

Add to Reading List

Source URL: www.fda.gov

Language: English
20Laronidase (Aldurazyme), Biomarin Pharmaceutical Inc

Laronidase (Aldurazyme), Biomarin Pharmaceutical Inc

Add to Reading List

Source URL: www.fda.gov

Language: English